Serum uric acid and risk of CKD in type 2 diabetes

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 11, 2015, Pages 1921-1929

  de Cosmo, Salvatore ^a   Viazzi, Francesca ^a   Pacilli, Antonio ^a   Giorda, Carlo ^a   Ceriello, Antonio ^a   Gentile, Sandro ^a   Russo, Giuseppina ^a   Rossi, Maria C ^a   Nicolucci, Antonio ^a   Guida, Pietro ^a   Feig, Daniel ^a   Johnson, Richard J ^a   Pontremoli, Roberto ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; URIC ACID;

ADULT; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; URINALYSIS; AGED; BLOOD; COMPLICATION; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; URIC ACID;

EID: 84946726781     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03140315     Document Type: Article

References (36)

1. International Diabetes Foundation: IDF Diabetes Atlas. Sixth edition. 2014. Available at: http://www.idf.org/diabetesatlas/ 5e/Update2013
2. The US Renal Data System: USRDS 2014 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the U.S. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2014
3. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR; UKPDS Group: Development and progression of nephropathy in type 2 diabetes: TheUnited Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232, 2003
4. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX: Chronic kidney disease and mortality risk: A systematic review. J Am Soc Nephrol 17: 2034-2047, 2006
5. Ninomiya T, Perkovic V, deGalan BE, Zoungas S, Pillai A, Jardine M, Patel A, Cass A, Neal B, Poulter N, Mogensen CE, Cooper M, Marre M, Williams B, Hamet P, Mancia G, Woodward M, Macmahon S, Chalmers J; ADVANCE Collaborative Group: Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 20: 1813-1821, 2009
6. Reidy K, Kang HM, Hostetter T, Susztak K: Molecular mechanisms of diabetic kidney disease. J Clin Invest 124: 2333-2340, 2014
7. Pezzolesi MG, Krolewski AS: The genetic risk of kidney disease in type 2 diabetes. Med Clin North Am 97: 91-107, 2013
8. Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, Gao P, Tian XJ, Liu JS, Zhu ZH, Huang K, Zhang C: High serum uric acid and increased risk of type 2 diabetes: A systemic review and meta-analysis of prospective cohort studies. PLoS One 8: e56864, 2013
9. Viazzi F, Leoncini G, Vercelli M, Deferrari G, Pontremoli R: Serum uric acid levels predict new-onset type 2 diabetes in hospitalized patients with primary hypertension: The MAGIC study. Diabetes Care 34: 126-128, 2011
10. Johnson RJ, Nakagawa T, Sanchez-Lozada LG, Shafiu M, Sundaram S, Le M, Ishimoto T, Sautin YY, Lanaspa MA: Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes 62: 3307-3315, 2013
11. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 359: 1811-1821, 2008
12. Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E: Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 35: 99-104, 2012
13. Viazzi F, Leoncini G, Ratto E, Falqui V, Parodi A, Conti N, Derchi LE, Tomolillo C, Deferrari G, Pontremoli R: Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am J Hypertens 20: 1276-1282, 2007
14. Pinelli M, Bindi M, Moroni F, Castiglioni M: Relationship between serum uric acid levels and urinary albumin excretion in patients with heart failure. Acta Cardiol 63: 191-195, 2008
15. Rodilla E, Pérez-Lahiguera F, Costa JA, González C, Miralles A, Moral D, Pascual JM: Association between serum uric acid, metabolic syndrome and microalbuminuria in previously untreated essential hypertensive patients. Med Clin (Barc) 132: 1-6, 2009
16. Kim ES, Kwon HS, Ahn CW, Lim DJ, Shin JA, Lee SH, Cho JH, Yoon KH, Kang MI, Cha BY, Son HY: Serum uric acid level is associated with metabolic syndrome and microalbuminuria in Korean patients with type 2 diabetes mellitus. J Diabetes Complications 25: 309-313, 2011
17. Suzuki K, Konta T, Kudo K, Sato H, Ikeda A, Ichikawa K, Ueno Y, Kato T, Kayama T, Kubota I: The association between serum uric acid and renal damage in a community-based population: the Takahata study. Clin Exp Nephrol 17: 541-548, 2013
18. Oh CM, Park SK, Ryoo JH: Serum uric acid level is associated with the development of microalbuminuria in Korean men. Eur J Clin Invest 44: 4-12, 2014
19. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G: Hypouricemia and hyperuricemia in type 2 diabetes: Two different phenotypes. Eur J Clin Invest 31: 318-321, 2001
20. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E: Uric acid and chronic kidney disease: Which is chasing which? Nephrol Dial Transplant 28: 2221-2228, 2013
21. Miao Y, Ottenbros SA, Laverman GD, Brenner BM, Cooper ME, Parving HH, Grobbee DE, Shahinfar S, de Zeeuw D, Lambers Heerspink HJ: Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58: 2-7, 2011
22. Nicolucci A, Rossi MC, Arcangeli A, Cimino A, de Bigontina G, Fava D, Gentile S, Giorda C, Meloncelli I, Pellegrini F, Valentini U, Vespasiani G; AMD-Annals Study Group: Four-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics: The AMD-Annals initiative. Diabet Med 27: 1041-1048, 2010
23. De Cosmo S, Rossi MC, Pellegrini F, Lucisano G, Bacci S, Gentile S, Ceriello A, Russo G, Nicolucci A, Giorda C, Viazzi F, Pontremoli R; AMD-Annals Study Group: Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrol Dial Transplant 29: 657-662, 2014
24. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration): A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612, 2009
25. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS: Uric acid and incident kidney disease in the community. J Am Soc Nephrol 19: 1204-1211, 2008
26. Syrjänen J, Mustonen J, Pasternack A: Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy. Nephrol Dial Transplant 15: 34-42, 2000
27. Haririan A, Metireddy M, Cangro C, Nogueira JM, Rasetto F, Cooper M, Klassen DK, Weir MR: Association of serum uric acid with graft survival after kidney transplantation: A time-varying analysis. Am J Transplant 11: 1943-1950, 2011
28. Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group: Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 29: 1802-1809, 2011
29. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ: Arole for uric acid in the progression of renal disease. J Am Soc Nephrol 13: 2888-2897, 2002
30. Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J: Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67: 237-247, 2005
31. Ryu ES, Kim MJ, Shin HS, Jang YH, Choi HS, Jo I, Johnson RJ, Kang DH: Uric acid-induced phenotypic transition of renal tubular cells as a novel mechanism of chronic kidney disease. Am J Physiol Renal Physiol 304: F471-F480, 2013
32. Kosugi T, Nakayama T, Heinig M, Zhang L, Yuzawa Y, Sanchez-Lozada LG, Roncal C, Johnson RJ, Nakagawa T: Effect of lowering uric acid on renal disease in the type 2 diabetic db/db mice. Am J Physiol Renal Physiol 297: F481-F488, 2009
33. Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J: Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5: 1388-1393, 2010
34. Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47: 51-59, 2006
35. Goicoechea M, Garcia de Vinuesa S, Verdalles U, Verde E, Macias N, Santos A, Pérez de Jose A, Cedeño S, Linares T, Luño J. Allopurinol and progression of CKD and cardiovascular events: Long-term follow-up of a randomized clinical trial. Am J Kidney Dis 65: 543-549, 2015
36. Bhalla V, Zhao B, Azar KM, Wang EJ, Choi S, Wong EC, Fortmann SP, Palaniappan LP: Racial/ethnic differences in the prevalence of proteinuric and nonproteinuric diabetic kidney disease. Diabetes Care 36: 1215-1221, 2013